Search results | wound

Reports

Wound Healing Partnering

Wound Healing Partnering report provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Top 15 most partnered therapeutic trends in pharma industry

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Dermatology partnering – recent deals analysis 2009-2014

Partnering in the last decade has seen an increase in dermatology with an rise specifically in modern diagnostic technologies.

Regenerative medicine

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to…

Johnson & Johnson

Johnson & Johnson is a top pharmaceutical company based in New Brunswick NJ, USA

Therapeutic partnering

Partnering with a therapeutic end point in mind.

Smith & Nephew recommended for 3-way split

Smith & Nephew  is suggested to split itself in 3-way by  Investec.

Ranbaxy: Partnering activity 2009-2014

Ranbaxy, a research based big pharma company with its headquarters in India, has announced 14 partnering / licensing deals since 2009, with 5 deals in 2010 alone.

Top 15 Most Partnered Therapeutic Targets

A recent study by Current Partnering identifies the most partnered therapeutic targets in recent years. Updated version of this article available here Top 15 most partnered therapeutic trends in pharma industry 2014

Dealtalk: Smith & Nephew CEO Has $1.5 Billion for Acquisitions

Smith & Nephew, the U.K.’s biggest medical device maker, has $1.5 billion to spend on acquisitions and is scouting wound-care companies in the U.S. as well as potential deals in trauma and sports medicine, according to dealtalk.

Johnson & Johnson: Company profile

Johnson & Johnson, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Events

Sorry, your search returned no results.


Deals

AMAG has acquired women’s heath specialist, Lumara Health

AMAG Pharmaceuticals has acquired women’s health company Lumara Health for $675 million.

Torrent enters into m&a deal with Elder pharma

Torrent pharma acquires Elder for $324 million in a m&a deal.

Kinetic Concepts announces merger and acquisition of Systagenix

Kinetic Concepts announces merger and acquisition agreement of  UK-based Systagenix, an established provider of advanced wound care products, for a purchase price of $485 million

Cardinal announces acquisition plans for AssuraMed for $2.07 billion

Cardinal Health announced acquisition plans to acquire AssuraMed, for $2.07 billion, or $1.94 billion, net of the present value of tax benefits.

A strategic M&A deal between Smith & Nephew & Healthpoint Biotherapeutics for $782 million

Smith & Nephew has signed an M&A agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash.

Pharma news: Kinetic Concepts unloads therapeutic support biz for $275 million to Getinge

Kinetic Concepts made huge pharma news with its announcement of entering into a definitive agreement to sell its Therapeutic Support Systems business to Getinge AB  for a total enterprise value of $275 million, on a debt free and cash free basis.

EQT VI buys BSN Medical in pharma deals acquisition agreement

EQT VI has agreed to buy medical device manufacturer BSN Medical from Montagu Private Equity for €1.8 billion (£1.4 billion)  in a definitive pharma deals acquisition agreement

Merck negotiates non-exclusive rights to Protein Sciences expresSF

Merck & Co negotiated nonexclusive rights to Protein Sciences’ expresSF+ serum-free insect cell line (SF+) and related technology for vaccine research, and an exclusive license to use the overall PS platform for commercial production of a specific vaccine candidate.

AstraZeneca may rethink aversion to big deals

Written by Allison Connolly for Bloomberg.  AstraZeneca’s pledge to avoid big acquisitions may be tested after setbacks for three of the company’s most promising drugs in development.

Sanofi-Aventis and Sunnybrook Health Sciences agree to develop treatment for diabetic foot ulcers

Sanofi-aventis and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds.